#South Korea #Seoul #PCR Testing #Seegene #CURECA

Overview of CURECA

Seegene Inc., a global leader in molecular diagnostic solutions, has recently introduced an innovative product, CURECA, which promises to revolutionize the automation of PCR (Polymerase Chain Reaction) testing. At the recent ESCMID Global 2025 event held in Vienna, Austria, Seegene unveiled a concept video, garnering significant attention from industry professionals.

Concept Introduction

The CURECA system demonstrates a comprehensive approach to automating the entire PCR testing workflow, from sample handling to result analysis. Designed with a modular structure, it allows for seamless integration into various laboratory settings, catering to the diverse needs of diagnostics professionals.

During its presentation, over 2300 attendees, including dignitaries from Italy, Germany, and other countries, expressed keen interest in the CURECA concept. Young-Seag Baeg, the head of Strategy and Planning at Seegene, elaborated on the system's groundbreaking capabilities, emphasizing its potential to eliminate manual errors associated with conventional testing processes.

Key Features of CURECA

CURECA aims to streamline the workflow by automating numerous stages involved in PCR diagnostics. The system is equipped to handle various sample types, including feces, urine, blood, and sputum, thus simplifying the pre-treatment processes that typically require extensive manual intervention. Industry experts have highlighted that this automation represents a transformative shift, making diagnostic procedures more efficient and reliable.

Personalized Customizable Pre-Treatment System (CPS)

At the heart of CURECA is the Customizable Pre-Treatment System (CPS), which has been developed to automate the pre-treatment of primary sample tubes. According to Baeg, this modular system optimizes pre-treatment processing primarily for molecular diagnostics, but also caters to clinical chemistry and immunology assays.

Modular Design Advantage

What truly sets CURECA apart is its modular architecture that supports customization based on laboratory-specific needs. This flexibility allows laboratories to implement tailored workflows, ensuring high-quality results with minimal dependency on standardized setups. This adaptability not only maximizes space efficiency but also addresses the challenges posed by limited laboratory resources.

Industry Reception

The feedback received during the ESCMID event was overwhelmingly positive. Attendees recognized the potential of CURECA to enhance laboratory throughput and reduce the time to report results significantly. Many professionals expressed hope that the integration of CURECA with their diagnostic toolkits could lead to synergies, improving both efficiency and accuracy.

Comments from various industry experts captured the excitement surrounding CURECA:

• - "A fully automated PCR diagnostic solution like CURECA eliminates human errors and allows for efficient testing without time constraints."
• - "Automating pre-processing could dramatically change the landscape of molecular diagnostics. We're ready for this kind of innovation."

Future Developments

Looking ahead, Seegene plans to showcase the tangible version of CURECA at the upcoming ADLM 2025 event in Chicago, where collaborations and further developments may take shape. The company aims to reach a broad range of laboratories, including small to medium-sized facilities, facilitating easy access to advanced diagnostic technologies.

Conclusion

Jong-Yoon Chun, CEO of Seegene, emphasizes the enthusiasm from the global audience towards CURECA's concept. He believes that this product has the potential to catalyze a significant change in the global landscape of PCR diagnostics, ultimately paving the way for efficient and effective healthcare solutions. With its innovative approach to automation, CURECA represents a promising advancement in the field of molecular diagnostics.